Stridh A, Pontén M, Arver S, et al.. Placebo responses among men with erectile dysfunction enrolled in phosphodiesterase 5 inhibitor trials. A systematic review and meta-analysis. JAMA Network Open 2020;3:20 de marzo. [Ref.ID 103574]

Ritchie A, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?. Lancet 2020:24 de marzo. [Ref.ID 103571]

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al.. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020:18 de marzo. [Ref.ID 103564]

Corbella J. Un fármaco antigripal, la nueva esperanza ante el coronavirus. La Vanguardia 2020:20 de marzo. [Ref.ID 103562]

Parsons L. EMA calls for pooled EU research into COVID-19 therapies. PMLiVE 2020:19 de marzo. [Ref.ID 103556]

Savage RD, Visentin JD, Bronskill SE, Wang X, Gruneir A, Giannakeas V, Guan J, Lam K, Luke MJ, Read SH, Stall NM, Wu W, Zhu L, Rochon PA, McCarthy LM. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern Med 2020:24 de febrero. [Ref.ID 103548]

Kondo KK, Morasco BJ, Nugent SM, Ayers CK, O'Neil ME, Freeman M, Kansagara D. Pharmacotherapy for the treatment of cannabis use disorder: a systematic review. Ann Intern Med 2020;164:3 de marzo. [Ref.ID 103546]

Dyer O. Cochrane reviewer sues Roche for claiming Tamiflu could slow flu pandemic. BMJ 2020;368:31 de enero. [Ref.ID 103541]

Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. Tolerability of antiseizure medications in individuals with newly diagnosed epilepsy. JAMA Neurology 2020:1. [Ref.ID 103540]

Kranzler HR, Feinn R, Morris P, Hartwell EE. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction 2019;114:septiembre. [Ref.ID 103238]

Simó Miñana J. Guerras médicas: a propósito del ensayo EXCEL . Salud, dinero y atención primaria 2019:15 de diciembre. [Ref.ID 103225]

Hermida RC, Crespo JJ, Domínguez-Sardina M, et al.. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2019:septiembre. [Ref.ID 103201]

Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen RJ, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394:24 de octubre. [Ref.ID 103199]

Anónimo. Outbreak of lung injury associated with e-cigarette use, or vaping. CDC 2019:3 de octubre. [Ref.ID 103188]

Korol S, White M, O'Meara E, Rouleau JL, White-Guay B, Dorais M, Ahmed A, de Denus S, Perreault S. Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?. Eur J Clin Pharmacol 2019;75:837-47. [Ref.ID 103176]

Young K. No evidence haloperidol helps in hospital delirium. Journal Watch 2019:3 de septiembre. [Ref.ID 103168]

Finnerub NB. Nonnarcotic methods of pain management. N Engl J Med 2019;380:20 de junio. [Ref.ID 103139]

Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, Oprescu AM, Salsitz E. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial. Am J Psychiatry 2019:21 de mayo. [Ref.ID 103125]

Haight BR, Learned SM, Lafont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Linq W, Heidbreder C, RB-US-13-0001 Study Investigators. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019;393:23 de febrero. [Ref.ID 103111]

Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues A, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow C-M, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology 2019:6 de marzo. [Ref.ID 103052]